Metformin × adverse events & safety

SynthesisMedicine2017

Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.

Shujuan Ma et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2017

Randomised comparison

Probably lowered adverse events & safety

−48%−60% to −32%

Bigger than 8 in 10 for adverse events & safety

As reported

OR 0.52, 95% CI 0.40–0.68

One number in the abstract

the abstract, start to end

the ratio of liver cancer by 48% (OR = 0.52; 95% CI, 0.40-0.68) compared

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
OR 0.520.40–0.68
MetforminAdverse events & safety

Metformin × adverse events & safetyharms?mixed

unlikelylikely
0.27not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

47 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28489794